SynBioWatch Press Release: For Immediate Release April 15, 2013 Contact: Lisa Archer, Gopal Dayaneni, or Tina Stevens, , (510) 982-1285, info@SynBioWatch.org Pharmaceutical giant Sanofi Aventis and Amyris Biotech founder Jay Keasling have announced that they intend to replace the entire world supply of the World Health Organization’s preferred anti-malarial treatment derived from botanical artemisinin with a semisynthetic product which employs synthetic biology, a controversial, unregulated biotechnology. Speaking at a conference in Cambridge, UK, Keasling said, “Moves [More]
by Jim Thomas Originally published by the Guardian UK Artemisinin breakthrough by synthetic biologists threatens to open new front in battle between microbes and people In the constant fight between microbes and people, attempts to rein in the malarial parasite have just taken an interesting turn. On Thursday April 11 the founder of Amyris Biotech triumphantly announced production of 70m doses of the anti-malarial compound artemisinin. This sounds like good news for poor people but may be [More]
Watch an archived broadcast of East Bay Conversations: When Green Tech Isn’t Clean Tech (3/21/2013) Synthetic biology includes creating novel life forms using DNA not found in nature, promising “green” fuel, cosmetics, cures, and more. Geoengineering promises techno fixes for climate change, including limiting sunlight and removing CO2 from the air. ETC Group’s technology watchdog Jim Thomas and Fibershed Founder Rebecca Burgess tell us what we’re not hearing from promoters about these “false solutions” — their land grabs, environmental and safety risks, and threats to “real green” technology solutions.